Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study (a Placebo Controlled, Randomized, Double-blind Comparative Study and an Open-label, Uncontrolled Study) to Evaluate the Efficacy and Safety of GSK1358820 in Patients With Post-stroke Upper Limb Spasticity

NCT03261167 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03261167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03261167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study (a Placebo Controlled, Randomized, Double-blind Comparative Study and an Open-label, Uncontrolled Study) to Evaluate the Efficacy and Safety of GSK1358820 in Patients With Post-stroke Upper Limb Spasticity
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
August 2, 2017
Completion date
January 10, 2019
Enrollment
124 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

spasticity, post-stroke